STOCKS TELEGRAPH

Tag: BriaCell

  • BriaCell Therapeutics (BCTX) Sees Stock Boost On Promising Trial News

    BriaCell Therapeutics (BCTX) Sees Stock Boost On Promising Trial News

    As of the last check today, BriaCell Therapeutics Corp. (NASDAQ: BCTX) shares were trading 23.20% up at $4.62 on the stock charts. The surge followed the company’s positive clinical trial results.

    Excellent Results for HR+ Metastatic Breast Cancer

    Following the publication of revised results from its Phase 2 study assessing the Bria-IMT regimen in conjunction with checkpoint inhibitors (CPI), which demonstrated improved survival outcomes in patients with metastatic breast cancer (MBC), BCTX stock experienced a strong increase.

    Patients with late-stage MBC, especially those with hormone receptor-positive (HR+) illness, were the focus of the Phase 2 investigation. Twenty-five of the 37 patients who received treatment with BriaCell’s current pivotal Phase 3 formulation of Bria-IMT were found to be HR+.

    The median survival for these patients was 17.3 months, which was higher than the 14.4-month survival with TRODELVY, an antibody-drug conjugate (ADC) that is thought to be the standard of therapy for this population.

    Boosting Triple-Negative Breast Cancer Outcomes

    In the triple-negative breast cancer (TNBC) group, a particularly difficult subtype devoid of HER2, progesterone, and estrogen receptors, the Bria-IMT + CPI regimen also produced noteworthy outcomes. While survival in this group was comparable to that achieved with TRODELVY, it exceeded traditional chemotherapy outcomes by 70%, underscoring the regimen’s therapeutic potential.

    Well-Tolerated Therapy Shows Broad Potential

    There have been no documented treatment-related discontinuations as of yet, indicating that the Bria-IMT regimen has shown excellent tolerability. These results support BriaCell’s theory that Bria-IMT and CPI together might provide HR+ and TNBC patients—groups who presently have few therapy options and dismal prognoses—with a useful treatment option.

    Of the 54 patients with MBC who were significantly pre-treated in BriaCell’s Phase 2 study, 37 were given the formulation that is currently being employed in its key Phase 3 trial. BCTX will continue evaluating overall survival as the primary endpoint in this ongoing study, aiming to confirm the promising Phase 2 results and address the unmet medical needs in this difficult-to-treat population.

  • BriaCell Therapeutics Corp. (BCTX) Stock Undergoes Volatility Ahead of Expanded Cancer Platform Technology Announcement

    BriaCell Therapeutics Corp. (BCTX) Stock Undergoes Volatility Ahead of Expanded Cancer Platform Technology Announcement

    BriaCell Therapeutics Corp. (BCTX) stock prices were up by a hefty 8.96% as of the market closing on June 16th, 2021, bringing the price per share up to USD$6.57 at the end of the trading day. After-hours trading, however, saw the stock drop by 9.28%, bringing it down to USD$5.96.

    Oncology Therapeutics

    The company announced on June 16th, 2021 the advancement of its targeted oncology therapeutics into various respective immunotherapy cell lines. Among these are Bria-Pros for prostrate cancer, Bria-Mel for melanoma, and Bria-Lung for lung cancer. The treatment was most effective in breast cancer when patient HLA-type matched with the targeted immunotherapy, owing to the potential afforded to Briacell to identify patients most likely to respond to the treatment.

    HLA-Type Testing

    This innovative approach makes use of human leukocyte antigen (HLA-type) testing, which is both simple to use and widely available, making it a highly accessible resource. With the use of its proprietary cell engineering technology, the company is now developing off-the-shelf personalized immunotherapy for various cancer indications, which utilizes the HLA-matching platform technology.

    Bria-Pros

    Bria-Pros is an off-the-shelf personalized treatment for prostate cancer, which is the second most common cancer among men in the US and one of the leading causes of cancer deaths in men. Existing treatments for metastatic prostate cancer include immunotherapy, hormone therapy, chemotherapy, and targeted treatments. However, there is much ground left to be broken in prostate cancer therapies, seeing how none of the existing ones are curative.

    Bria-Mel

    Bria-Mel is personalized immunotherapy for melanoma, with off-the-shelf availability. With more than 80,000 melanoma diagnoses being administered in the US alone, the disease claims the lives of more than 8000 patients every year. Immunotherapy, targeted therapy, and chemotherapy are options in the treatment for advanced melanoma, with there being a large unaddressed need for new safe and effective therapies for melanoma.

    Bria-Lung

    Bria-Lung is designed as personalized immunotherapy for lung cancer, being available off-the-shelf. Being the third most common type of cancer in the world, more than 130,000 Americans succumb to it every year. The most common form of lung cancer is called non-small cell lung cancer (NSCLC) and its spread (metastasis). With treatments including targeted therapies, immunotherapy, and chemotherapy, no treatment is likely to cure the cancers, indicating a large unmet need.

    Future Outlook for BCTX

    Armed with the development of accessible treatments that the company hopes will address large sections of unmet need, BCTX is poised to push for the proliferation of the treatments to expand and consolidate their market footprint. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.